Ana Carrion-Gelabert
Family · Washington, DCNPI 1023178233
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,197 of the $7,244 with a category attached, or 85.5%. 34 manufacturers reported payments, led by AbbVie at 32.4% of the total. 2025 is the largest year on record at $3,065, more than ten times the $129 reported in 2021. Among family clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $27.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Livanova USA, Inc.$1K
- Pfizer$472
- Teva Pharmaceuticals USA, Inc.$400
- Neurocrine Biosciences, Inc.$356
- Lilly USA, LLC$267
- plus $2K from 28 others
What the payments were for
- Travel & lodging$96013%
- Food & beverage$6,19786%
- Education$871%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 102 | $2,349 |
| Livanova USA, Inc. | 5 | $1,384 |
| Pfizer | 37 | $472 |
| Teva Pharmaceuticals USA, Inc. | 18 | $400 |
| Neurocrine Biosciences, Inc. | 18 | $356 |
| Lilly USA, LLC | 14 | $267 |
| UCB, Inc. | 10 | $255 |
| Lundbeck LLC | 6 | $219 |
| Neurelis, Inc. | 5 | $214 |
| Nevro Corp. | 1 | $144 |
| Eisai Inc. | 1 | $124 |
| Insightec,inc | 1 | $110 |
| Jazz Pharmaceuticals Inc. | 3 | $109 |
| Acadia Pharmaceuticals Inc | 4 | $99 |
| SK Life Science, Inc. | 4 | $90 |
| Otsuka America Pharmaceutical, Inc. | 3 | $85 |
| Axsome Therapeutics, Inc. | 3 | $71 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $58 |
| MDD US Operations, LLC | 1 | $57 |
| Amgen | 2 | $55 |
| Amneal Pharmaceuticals LLC | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 2 | $40 |
| Biogen | 2 | $34 |
| Tonix Medicines, Inc. | 2 | $32 |
| Impel Pharmaceuticals LLC | 2 | $30 |
| Genentech USA, Inc. | 1 | $22 |
| Medtronic | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Aquestive Therapeutics, Inc. | 1 | $19 |
| Octapharma USA, Inc. | 1 | $19 |
| Cranial Technologies, Inc | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| AstraZeneca | 1 | $14 |
| Aucta Pharmaceuticals, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,244 in reported general payments places this provider in the 95th percentile of 392 family providers in District of Columbia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 61 | $91,546 |
| QuliptaAtogepant | 49 | $60,543 |
| UbrelvyUbrogepant | 40 | $48,481 |
| Emgality PenGalcanezumab-Gnlm | 39 | $34,665 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $16,436 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 23 | $16,145 |
| Donepezil Hcl | 147 | $4,444 |
| Memantine Hcl | 90 | $4,289 |
| Levetiracetam | 63 | $3,375 |
| Carbamazepine | 47 | $2,126 |
| Quetiapine Fumarate | 50 | $1,762 |
| Olanzapine | 13 | $1,483 |
| Sertraline Hcl | 133 | $1,203 |
| Gabapentin | 101 | $1,177 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 40 | $931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $2,349 | $109,02489 claims |
| PfizerNurtec Odt | $472 | $91,54661 claims |
| Lilly USA, LLCOlanzapine | $267 | $1,48313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 392 family providers in District of Columbia.
Other family in Washington
- Amy StewartWashington$489K
- Kara CouchWashington$144K
- Laura XandersWashington$109K
- Laura MackeWashington$39K
- Cassandra ThompsonWashington$11K
- Sharmin DiazWashington$9K
- Emily BertrandWashington$8K
- Chanda CopelandWashington$7K
- Suad NsouliWashington$6K
- Mitchell WhartonWashington$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.